GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cohance Lifesciences Ltd (NSE:COHANCE) » Definitions » Purchase Of Investment

Cohance Lifesciences (NSE:COHANCE) Purchase Of Investment : ₹0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Cohance Lifesciences Purchase Of Investment?

Cohance Lifesciences's purchase of investment for the three months ended in Dec. 2024 was ₹0 Mil. It means Cohance Lifesciences spent ₹0 Mil on purchasing investments. Cohance Lifesciences's purchase of investment for the trailing twelve months (TTM) ended in Dec. 2024 was ₹0 Mil.

Compared with last quarter (₹0 Mil in Sep. 2024 ), Cohance Lifesciences spent the same money on purchasing investments in Dec. 2024 (₹0 Mil).

Cohance Lifesciences Purchase Of Investment Historical Data

The historical data trend for Cohance Lifesciences's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cohance Lifesciences Purchase Of Investment Chart

Cohance Lifesciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Purchase Of Investment
Get a 7-Day Free Trial - -2,005.83 -3,002.74 - -

Cohance Lifesciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Purchase Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cohance Lifesciences Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cohance Lifesciences Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Cohance Lifesciences's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Cohance Lifesciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cohance Lifesciences Ltd (NSE:COHANCE) » Definitions » Purchase Of Investment
Comparable Companies
BOM:543635 BOM:506943 BOM:532331 BOM:540222 NSE:GLAND BOM:532300 BOM:524494 BOM:506820 BOM:540596 BOM:532296 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
543064:India
Address
No. 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, TG, IND, 500081
Website
https://www.suvenpharm.com
Suven Pharmaceuticals Ltd is involved in developing and manufacturing intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology, and chemical companies. The company operates majorly in the Manufacturing (CRAMS) segment, which includes bulk drugs and intermediates under contract services. Its geographical segments include India, the USA, Europe, and the Rest of the World. The majority of the company's revenue comes from the Europe segment.

Cohance Lifesciences Headlines

No Headlines